$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416100475 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$38.10K	$38.10K	$38.10K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.410M	$2.420M	$5.020M
YoY Change	-51.99%	-33.15%	55.42%
% of Gross Profit
Research & Development	$11.62M	$15.25M	$9.617M
YoY Change	20.8%	0.73%	118.09%
% of Gross Profit
Depreciation & Amortization	$6.380K	$10.00K	$2.419K
YoY Change	163.75%		242.63%
% of Gross Profit
Operating Expenses	$14.03M	$17.68M	$14.64M
YoY Change	-4.17%	-5.76%	91.55%
Operating Profit	-$13.99M		-$14.60M
YoY Change	-4.18%		92.01%
Interest Expense	$242.4K	$30.00K	$237.7K
YoY Change	2.0%	-137.5%	5.0%
% of Operating Profit
Other Income/Expense, Net	$143.5K	$0.00	$25.12K
YoY Change	471.33%		-56.6%
Pretax Income	-$13.85M	-$17.61M	-$14.58M
YoY Change	-5.01%	-6.33%	93.18%
Income Tax
% Of Pretax Income
Net Earnings	-$13.85M	-$17.61M	-$14.58M
YoY Change	-5.0%	-6.3%	93.15%
Net Earnings / Revenue	-36352.96%	-46231.3%	-38266.79%
Basic Earnings Per Share
Diluted Earnings Per Share	-$283.2K	-$365.7K	-$354.8K
COMMON SHARES
Basic Shares Outstanding	54.10M shares	52.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.70M	$77.20M	$105.1M
YoY Change	-44.15%	-2.03%	96.45%
Cash & Equivalents	$6.800M	$55.06M	$86.00M
Short-Term Investments	$22.20M	$22.20M	$19.10M
Other Short-Term Assets	$11.70M	$308.3K	$701.9K
YoY Change	1566.99%	77.25%	-74.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$70.60M	$86.87M	$115.7M
YoY Change	-39.0%	1.95%	105.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$300.0K	$47.12K	$24.82K
YoY Change	1108.65%	131.48%
Goodwill		$799.4K	$799.4K
YoY Change		0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$26.50M	$25.00M
YoY Change
Other Assets	$1.900M	$171.2K	$130.6K
YoY Change	1354.53%	24.86%	70.94%
Total Long-Term Assets	$29.50M	$26.60M	$1.531M
YoY Change	1826.96%	1636.44%	-18.31%
TOTAL ASSETS
Total Short-Term Assets	$70.60M	$86.87M	$115.7M
Total Long-Term Assets	$29.50M	$26.60M	$1.531M
Total Assets	$100.1M	$113.5M	$117.3M
YoY Change	-14.64%	30.81%	101.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.100M	$9.300M	$8.900M
YoY Change	-8.99%	132.5%	456.25%
Accrued Expenses	$400.0K	$800.0K	$200.0K
YoY Change	100.0%	14.29%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$300.0K
YoY Change	-33.33%	-33.33%
Total Short-Term Liabilities	$8.894M	$10.53M	$9.553M
YoY Change	-6.9%	105.59%	380.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.700M	$1.400M	$1.500M
YoY Change	13.33%	-6.67%	-6.25%
Total Long-Term Liabilities	$1.700M	$1.400M	$1.500M
YoY Change	13.33%	-6.67%	-11.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.894M	$10.53M	$9.553M
Total Long-Term Liabilities	$1.700M	$1.400M	$1.500M
Total Liabilities	$10.60M	$11.90M	$11.04M
YoY Change	-3.97%	79.08%	194.96%
SHAREHOLDERS EQUITY
Retained Earnings		-$158.1M	-$109.8M
YoY Change		66.13%
Common Stock		$54.10K	$47.47K
YoY Change		20.28%	26.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$234.3K	$234.3K
YoY Change		0.0%	0.0%
Treasury Stock Shares	41.31K shares	41.31K shares	41.31K shares
Shareholders Equity	$89.40M	$101.6M	$106.2M
YoY Change
Total Liabilities & Shareholders Equity	$100.1M	$113.5M	$117.3M
YoY Change	-14.64%	30.81%	101.58%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	-$13.85M	-$17.61M	-$14.58M
YoY Change	-5.0%	-6.3%	93.15%
Depreciation, Depletion And Amortization	$6.380K	$10.00K	$2.419K
YoY Change	163.75%		242.63%
Cash From Operating Activities	-$16.67M	-$12.90M	-$8.880M
YoY Change	87.73%	-14.63%	6.6%
INVESTING ACTIVITIES
Capital Expenditures	$282.3K	$20.00K	$6.883K
YoY Change	4000.84%	-200.0%	117.47%
Acquisitions
YoY Change
Other Investing Activities	-$1.640M	$2.470M	$3.850M
YoY Change	-142.6%	-127.08%
Cash From Investing Activities	-$1.920M	$2.470M	$3.840M
YoY Change	-150.0%	-127.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	20.00K	35.33M
YoY Change	-99.97%	-99.93%	102.58%
NET CHANGE
Cash From Operating Activities	-16.67M	-12.90M	-8.880M
Cash From Investing Activities	-1.920M	2.470M	3.840M
Cash From Financing Activities	10.00K	20.00K	35.33M
Net Change In Cash	-18.58M	-10.41M	30.29M
YoY Change	-161.34%	-521.46%	232.49%
FREE CASH FLOW
Cash From Operating Activities	-$16.67M	-$12.90M	-$8.880M
Capital Expenditures	$282.3K	$20.00K	$6.883K
Free Cash Flow	-$16.95M	-$12.92M	-$8.887M
YoY Change	90.76%	-14.38%	6.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	1337908	USD
CY2015Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	8279431	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9617339	USD
CY2016Q1	us-gaap	Long Term Investments LongTermInvestments	26458226	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	25003032	USD
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	152917	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	211549	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8893864	USD
CY2016Q1	us-gaap	Licenses Revenue LicensesRevenue	38095	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	38095	USD
CY2016Q1	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	386925	USD
CY2016Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	11230415	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11617340	USD
CY2016Q1	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	1312040	USD
CY2015Q1	tgtx	Non Cash Compensation General And Administrative Expenses NonCashCompensationGeneralAndAdministrativeExpenses	4019120	USD
CY2016Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1100871	USD
CY2015Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1004487	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2412911	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5023607	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	14030251	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	14640946	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13992156	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14602851	USD
CY2016Q1	us-gaap	Interest Income Other InterestIncomeOther	84862	USD
CY2015Q1	us-gaap	Interest Income Other InterestIncomeOther	22132	USD
CY2016Q1	us-gaap	Depreciation Depreciation	6380	USD
CY2015Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	80597	USD
CY2016Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	128329	USD
CY2015Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4159055	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2250490	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	242405	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	237657	USD
CY2016Q1	tgtx	Change In Fair Value Of Non Current Note Payable ChangeInFairValueOfNonCurrentNotePayable	301037	USD
CY2015Q1	tgtx	Change In Fair Value Of Non Current Note Payable ChangeInFairValueOfNonCurrentNotePayable	240641	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	143494	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25116	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-13848662	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	-14577735	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48908278	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41088752	shares
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5357028	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1698965	USD
CY2015Q1	us-gaap	Depreciation Depreciation	2419	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	4194	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-21915	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4434813	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1575974	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-38095	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-38096	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8882353	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16673541	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6883	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	282261	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3843117	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1923531	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	408286	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22163	USD
CY2015Q1	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	34941049	USD
CY2016Q1	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	35329897	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14163	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30290661	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18582909	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55713784	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86004445	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1060	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1008	USD
CY2015Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	19438	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5341	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-25913	USD
CY2016Q1	tgtx	Proceeds From Maturities ProceedsFromMaturities	9000000	USD
CY2015Q1	tgtx	Proceeds From Maturities ProceedsFromMaturities	3850000	USD
CY2016Q1	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	10641270	USD
CY2015Q1	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	0	USD
CY2016Q1	tgtx	Period Anticipated Sufficient To Fund Operating Cash Flow PeriodAnticipatedSufficientToFundOperatingCashFlow	P24M
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	85300000	USD
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8265583	USD
CY2016Q1	us-gaap	Cash Cash	29636560	USD
CY2015Q4	us-gaap	Cash Cash	46795746	USD
CY2016Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	48682484	USD
CY2016Q1	us-gaap	Held To Maturity Securities Unrecognized Holding Gains HeldToMaturitySecuritiesUnrecognizedHoldingGains	51463	USD
CY2016Q1	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	600000	USD
CY2016Q1	tgtx	Prepaid Manufacturing PrepaidManufacturing	9800000	USD
CY2015Q4	tgtx	Prepaid Manufacturing PrepaidManufacturing	7700000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8382986	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6869500	shares
CY2016Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	6841860	USD
CY2016Q1	us-gaap	Held To Maturity Securities Unrecognized Holding Losses HeldToMaturitySecuritiesUnrecognizedHoldingLosses	7019	USD
CY2016Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	48726928	USD
CY2015Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	47169544	USD
CY2015	us-gaap	Held To Maturity Securities Unrecognized Holding Gains HeldToMaturitySecuritiesUnrecognizedHoldingGains	0	USD
CY2015	us-gaap	Held To Maturity Securities Unrecognized Holding Losses HeldToMaturitySecuritiesUnrecognizedHoldingLosses	108668	USD
CY2015Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	47060876	USD
CY2010Q1	us-gaap	Notes Issued1 NotesIssued1	15500000	USD
CY2010Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1125
CY2010Q1	tgtx	Percentage Of Cash Proceeds From Operation To Repay Convertible Debt PercentageOfCashProceedsFromOperationToRepayConvertibleDebt	0.5	pure
CY2016Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	152917	USD
CY2016Q1	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	152917	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	211549	USD
CY2015Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	211549	USD
CY2016Q1	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	242405	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-301037	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	152917	USD
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	20800000	USD
CY2016Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2016Q1	us-gaap	Notes Payable NotesPayable	152917	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	211549	USD
CY2010Q1	tgtx	Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt	0.5	pure
CY2011Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2016Q1	tgtx	Additional Amount Receivable On Achievement Of Pre Specified Milestones AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones	5000000	USD
CY2016Q1	us-gaap	Deferred Revenue DeferredRevenue	1500000	USD
CY2016Q1	us-gaap	Prepaid Rent PrepaidRent	1151163	USD
CY2015Q4	us-gaap	Prepaid Rent PrepaidRent	0	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	389554	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309	shares
CY2016Q1	tgtx	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	22163	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54118722	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54095110	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54077413	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54053801	shares
CY2016Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1698965	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	1151163	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="COLOR: black">Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="COLOR: black"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the consolidated financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="COLOR: black">Credit Risk</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	211549	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5357028	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1698965	USD
CY2010Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P5Y
CY2016Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2015	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2016Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1125
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	1500000	USD
CY2015	us-gaap	Licenses Revenue LicensesRevenue	200000	USD
CY2016Q1	tgtx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	389554	USD
CY2015Q1	tgtx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD

Files In Submission

Name	View Source	Status
0001144204-16-100475-index-headers.html	Edgar Link	pending
0001144204-16-100475-index.html	Edgar Link	pending
0001144204-16-100475.txt	Edgar Link	pending
0001144204-16-100475-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20160331.xml	Edgar Link	completed
tgtx-20160331.xsd	Edgar Link	pending
tgtx-20160331_cal.xml	Edgar Link	unprocessable
tgtx-20160331_def.xml	Edgar Link	unprocessable
tgtx-20160331_lab.xml	Edgar Link	unprocessable
tgtx-20160331_pre.xml	Edgar Link	unprocessable
v438437_10q.htm	Edgar Link	pending
v438437_ex31-1.htm	Edgar Link	pending
v438437_ex31-2.htm	Edgar Link	pending
v438437_ex32-1.htm	Edgar Link	pending
v438437_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2016 Q1 Form 10-Q Financial Statement

#000114420416100475 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2016 Q1 Form 10-Q Financial Statement

#000114420416100475 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx